



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com  
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory

**Demo Report**

Report Issued 04/02/2020 14:55

**Patient Name** 8151B-POS  
**Patient ID** 8151B-POS  
**Chain** 20000882  
**Age Not Given** **DOB** Not Given  
**Gender** Not Given  
**Workorder** 20000882

To: **88888**  
Forensic Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

Page 1 of 5

**Positive Findings:**

<u>Compound</u>	<u>Result</u>	<u>Units</u>	<u>Matrix Source</u>
Ethanol	85 ±6	mg/dL	001 - Blood
Blood Alcohol Concentration (BAC)	0.085 ±0.006	g/100 mL	001 - Blood
Alprazolam	50 ±10	ng/mL	001 - Blood
Delta-9 THC	50 ±10	ng/mL	001 - Blood
Cocaine	50 ±11	ng/mL	001 - Blood
Fentanyl	5.0 ±0.9	ng/mL	001 - Blood

Quantitative results are reported as Result +/- Uncertainty of Measurement (UM). Ethanol results are reported at a coverage probability of 99.73%; all other analytes are reported at a coverage probability of 95.45%.

See Detailed Findings section for additional information

**Testing Requested:**

<u>Analysis Code</u>	<u>Description</u>
8151B	DUID/DRE Panel (w/Alcohol) ProofPOSITIVE®, Blood (Forensic)

**Specimens Received:**

<u>ID</u>	<u>Tube/Container</u>	<u>Volume/ Mass</u>	<u>Collection Date/Time</u>	<u>Matrix Source</u>	<u>Miscellaneous Information</u>
001	Clear vial	Not Given	Not Given	Blood	

All sample volumes/weights are approximations.  
Specimens received on 03/31/2020.

**Detailed Findings:**

Analysis and Comments	Result	Units	Rpt. Limit	Specimen Source	Analysis By
Ethanol	85	mg/dL	10	001 - Blood	Headspace GC
Blood Alcohol Concentration (BAC)	0.085	g/100 mL	0.010	001 - Blood	Headspace GC
Ethanol	Confirmed	mg/dL	10	001 - Blood	Headspace GC
Alprazolam	50	ng/mL	5.0	001 - Blood	LC-MS/MS
Delta-9 THC	50	ng/mL	0.50	001 - Blood	LC-MS/MS
Cocaine	50	ng/mL	20	001 - Blood	GC/MS
Fentanyl	5.0	ng/mL	0.10	001 - Blood	LC-MS/MS

**Other than the above findings, examination of the specimen(s) submitted did not reveal any positive findings of toxicological significance by procedures outlined in the accompanying Analysis Summary.**

**Reference Comments:**

1. Alprazolam (Xanax®) - Blood:

Alprazolam is a low-dose benzodiazepine used for the treatment of anxiety disorders and short-term relief of anxiety associated with depressive symptoms. Alpha-hydroxyalprazolam is an active metabolite of alprazolam. They share the actions and adverse reactions of other CNS-depressants. Alcohol greatly enhances the activity of benzodiazepines. Common adverse effects of alprazolam include drowsiness, fatigue, sedation, dizziness, weakness, unsteadiness and disorientation. Signs of CNS depression can include the presence of horizontal gaze nystagmus, lack of convergence of the eyes, normal pupil size with slow reaction to light and reduced pulse and blood pressure. For anxiety, daily doses of 0.8 to 4 mg are effective, whereas for phobic and panic disorders, 6 to 9 mg daily is recommended. Reported therapeutic plasma concentrations of alprazolam are proportional to dose given: 3 mg/day produced steady-state levels of 30 ng/mL; 6 mg/day: 60 ng/mL; and 9 mg/day: 100 ng/mL. In a population of 219 drivers arrested for driving under the influence, Alprazolam concentrations ranged from 5 - 1580 ng/mL, with a mean of 103 ng/mL. Other drugs may also have been present. Studies confirm that alprazolam is capable of causing significant impairment to driving and psychomotor abilities across a wide range of concentrations.

2. Blood Alcohol Concentration (BAC) - Blood:

I certify that I am the analyst of record for this report. In that capacity I am authorized by NMS Labs to provide the final analytical review of the results in this case. This report cannot be released without my review, and I am responsible for the accuracy of results contained herein. This laboratory is nationally accredited by the American Board of Forensic Toxicology (ABFT) and ANSI-ASQ National Accreditation Board-American Society of Crime Lab Directors/Lab Accreditation Board-International (ANAB-ASCLD/LAB-International), and complies with accreditation standards for internal chain of custody, standard operating procedures, analysis of appropriate blanks, calibrators and controls, and other quality control and quality assurance measures, all of which I am familiar with, and which help ensure test result accuracy. I have considered all the information available to me at this time, and it is my opinion and belief that the analysis was properly performed in compliance with laboratory standards and policies, that the results are supported by the analytical data, and that the results accurately reflect the toxicological findings for this subject. If lawfully subpoenaed, I will testify to the above facts in a court of law.

3. Cocaine - Blood:

Cocaine is a DEA Schedule II controlled central nervous stimulant drug. Effects following cocaine use can include euphoria, excitement, restlessness, risk taking, sleep disturbance, and aggression. A period of mental and physical fatigue and somnolence follow the use of cocaine after the excitant-stimulant effects wear off. Cocaine is metabolized to the inactive compounds benzoylecgonine, ecgonine methyl ester, and ecgonine. Benzoylecgonine and ecgonine methyl ester can form from cocaine breakdown after death and even after sample collection. The average blood cocaine concentration in 906 impaired drivers was 87 ng/mL (range 5 - 2390 ng/mL). Blood cocaine concentrations in patients admitted to an emergency room for cocaine related medical complaints were 260 ng/mL (SD = 500 ng/mL). Cocaine concentrations in plasma following oral administration of 2 g/day over 6 days, averaged 1260 ng/mL.

**Reference Comments:**

4. Delta-9 THC (Active Ingredient of Marijuana) - Blood:

Delta-9-THC is the principle psychoactive ingredient of marijuana (cannabis, hashish). It is also the active component of the prescription medication Marinol®. Whole blood THC concentrations are typically half those in a corresponding plasma sample. After smoking a user-preferred 300 mcg/kg dose average plasma THC concentrations at 35 minutes were reported at 16.1 (range 4.7 - 30.9) ng/mL, and had declined to 1.5 (range 0.4 - 3.2) ng/mL after 190 minutes. Marijuana use causes relaxation, distorted perception, euphoria and feelings of well being, along with confusion, dizziness, somnolence, ataxia, speech difficulties, lethargy and muscular weakness. Effects of marijuana use on driving ability may include weaving, inattention, poor coordination and slowed reaction time with increased error rates in complex tasks. These effects worsen with increased THC concentrations. Peak effects typically last from 1-4 hours. THC concentrations in the blood decline rapidly after use, and may be undetectable within 1-3 hours following smoking. Numerous studies have associated marijuana use with impaired driving performance.

5. Ethanol (Ethyl Alcohol) - Blood:

Ethanol (beverage alcohol) is a central nervous system depressant. It causes impairment of cognitive, perceptual and psychomotor capabilities manifested as decrements in alertness, judgment, perception, coordination, response time and sense of care and caution. Potential effects on driving include, but are not limited to, weaving, crossing center or fog lines, failure to obey traffic signals, wide turns, inappropriate speed for conditions, and involvement in collisions. Generally, a person's level of intoxication will increase with rising blood alcohol concentration. Effects are more pronounced in individuals with limited tolerance, especially minors, however at blood alcohol concentrations of 80 mg/dL (0.08 g/100 mL or 0.08% w/v), virtually all individuals exhibit impairment on some critical driving measures.

Analysis performed in duplicate by, internally standardized, headspace Gas Chromatography (GC). The average of the two headspace GC results is reported.

NMS Labs is an approved Laboratory for Alcohol analysis in the Commonwealth of Pennsylvania.

6. Fentanyl (Duragesic®; Sublimaze®) - Blood:

Fentanyl is a DEA Schedule II synthetic morphine substitute anesthetic/analgesic. It is reported to be 80 to 200 times as potent as morphine and has a rapid onset of action as well as addictive properties.

It is reported that patients lost consciousness at mean plasma levels of fentanyl of 34 ng/mL when infused with 75 mcg/Kg over a 15 min period; peak plasma levels averaged 50 ng/mL.

After application of a fentanyl transdermal preparation (patch), serum fentanyl concentrations are reported to be in the following ranges within 24 hours:

25 mcg/hour patch: 0.3 - 1.2 ng/mL  
50 mcg/hour patch: 0.6 - 1.8 ng/mL  
75 mcg/hour patch: 1.1 - 2.6 ng/mL  
100 mcg/hour patch: 1.9 - 3.8 ng/mL

Following removal of the patch, serum fentanyl concentrations are reported to decrease with a mean elimination half-life of 17 hours (range, 13 to 22 hours).

The mean peak plasma serum fentanyl concentration in adults given an 800 mcg oral transmucosal fentanyl preparation over 15 minutes is reported at 2.1 ng/mL (range, 1.4 - 3.0 ng/mL) at approximately 0.4 hours.

Signs associated with fentanyl toxicity include severe respiratory depression, seizures, hypotension, coma and death. In fatalities from fentanyl, blood concentrations are variable and have been reported as low as 3 ng/mL.

Substance(s) known to interfere with the identity and/or quantity of the reported result: 4-methylphenethyl acetyl fentanyl

**Analysis Summary and Reporting Limits:**

All of the following tests were performed for this case. For each test, the compounds listed were included in the scope. The Reporting Limit listed for each compound represents the lowest concentration of the compound that will be reported as being positive. If the compound is listed as None Detected, it is not present above the Reporting Limit. Please refer to the Positive Findings section of the report for those compounds that were identified as being present.

Acode 54002B - Benzodiazepines Confirmation (DUID/DRE), Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

<u>Compound</u>	<u>Rpt. Limit</u>	<u>Compound</u>	<u>Rpt. Limit</u>
7-Amino Clonazepam	5.0 ng/mL	Flurazepam	2.0 ng/mL
Alpha-Hydroxyalprazolam	5.0 ng/mL	Hydroxyethylflurazepam	5.0 ng/mL
Alprazolam	5.0 ng/mL	Hydroxytriazolam	5.0 ng/mL
Chlordiazepoxide	20 ng/mL	Lorazepam	5.0 ng/mL
Clobazam	20 ng/mL	Midazolam	5.0 ng/mL
Clonazepam	2.0 ng/mL	Nordiazepam	20 ng/mL
Desalkylflurazepam	5.0 ng/mL	Oxazepam	20 ng/mL
Diazepam	20 ng/mL	Temazepam	20 ng/mL
Estazolam	5.0 ng/mL	Triazolam	2.0 ng/mL

Acode 54003B - Cannabinoids Confirmation (DUID/DRE), Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

<u>Compound</u>	<u>Rpt. Limit</u>	<u>Compound</u>	<u>Rpt. Limit</u>
11-Hydroxy Delta-9 THC	1.0 ng/mL	Delta-9 THC	0.50 ng/mL
Delta-9 Carboxy THC	5.0 ng/mL		

Acode 54004B - Cocaine and Metabolites Confirmation (DUID/DRE), Blood

-Analysis by Gas Chromatography/Mass Spectrometry (GC/MS) for:

<u>Compound</u>	<u>Rpt. Limit</u>	<u>Compound</u>	<u>Rpt. Limit</u>
Benzoylcegonine	50 ng/mL	Cocaine	20 ng/mL
Cocaethylene	20 ng/mL		

Acode 54459B - DUID/DRE Fentanyl and Acetyl Fentanyl Confirmation, Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

<u>Compound</u>	<u>Rpt. Limit</u>	<u>Compound</u>	<u>Rpt. Limit</u>
Acetyl Fentanyl	0.10 ng/mL	Norfentanyl	0.20 ng/mL
Fentanyl	0.10 ng/mL		

Acode 8151B - DUID/DRE Panel (w/Alcohol) ProofPOSITIVE®, Blood (Forensic)

-Analysis by Enzyme-Linked Immunosorbent Assay (ELISA) for:

<u>Compound</u>	<u>Rpt. Limit</u>	<u>Compound</u>	<u>Rpt. Limit</u>
Amphetamines	20 ng/mL	Methadone / Metabolite	25 ng/mL
Barbiturates	0.040 mcg/mL	Methamphetamine / MDMA	20 ng/mL
Benzodiazepines	20 ng/mL	Opiates	20 ng/mL
Buprenorphine / Metabolite	0.50 ng/mL	Oxycodone / Oxymorphone	10 ng/mL
Cannabinoids	10 ng/mL	Phencyclidine	10 ng/mL
Carisoprodol / Metabolite	500 ng/mL	Tramadol / Metabolite	50 ng/mL
Cocaine / Metabolites	20 ng/mL	Zolpidem	5.0 ng/mL
Fentanyl / Acetyl Fentanyl	0.50 ng/mL		



CONFIDENTIAL

Workorder 20000882  
Chain 20000882  
Patient ID 8151B-POS

Page 5 of 5

**Analysis Summary and Reporting Limits:**

-Analysis by Headspace Gas Chromatography (GC) for:

<u>Compound</u>	<u>Rpt. Limit</u>	<u>Compound</u>	<u>Rpt. Limit</u>
Acetone	5.0 mg/dL	Isopropanol	5.0 mg/dL
Ethanol	10 mg/dL	Methanol	5.0 mg/dL

-Analysis by Headspace Gas Chromatography (GC) for:

<u>Compound</u>	<u>Rpt. Limit</u>	<u>Compound</u>	<u>Rpt. Limit</u>
Acetone	5.0 mg/dL	Isopropanol	5.0 mg/dL
Ethanol	10 mg/dL	Methanol	5.0 mg/dL